Watch Ticker

Immix Biopharma, Inc. Common Stock

Go to Immix Biopharma, Inc. Common Stock Website

$2.75

-0.10 (-3.51%)

Live

Previous Close

$2.595

Day Range

$2.53 - $2.95

Previous Day Range

$2.57 - $2.92

Market Cap

$79.5 million USD

Day Vol.

519055

Previous Day Vol.

723314

Currency

USD

Primary Exchange

Nasdaq

Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific T...

Community

0 posts discussing

0

Watchers

0

Visitors

Recent News

Immix Biopharma, Inc. - Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis

Immix Biopharma's CAR-T cell therapy NXC-201 demonstrated positive clinical results in treating relapsed/refractory AL Amyloidosis, with a 75% complete response rate and a favorable safety profile.

Related tickers: IMMX.

Read Full Article

Immix Biopharma, Inc. - California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)

Immix Biopharma's subsidiary Nexcella has received an $8 million grant from the California Institute for Regenerative Medicine to support the clinical development of its CAR-T therapy NXC-201 for the treatment of relapsed/refractory AL Amyloidosis.

Related tickers: IMMX.

Read Full Article

Trending Tickers

Please sign in to view